IE45352B1 - Determation of polyunsaturated fat levels in body fluids - Google Patents

Determation of polyunsaturated fat levels in body fluids

Info

Publication number
IE45352B1
IE45352B1 IE1374/77A IE137477A IE45352B1 IE 45352 B1 IE45352 B1 IE 45352B1 IE 1374/77 A IE1374/77 A IE 1374/77A IE 137477 A IE137477 A IE 137477A IE 45352 B1 IE45352 B1 IE 45352B1
Authority
IE
Ireland
Prior art keywords
polyunsaturated fatty
body fluid
oxygen
fatty acids
cis
Prior art date
Application number
IE1374/77A
Other versions
IE45352L (en
Original Assignee
Chembro Holdings Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chembro Holdings Pty Ltd filed Critical Chembro Holdings Pty Ltd
Publication of IE45352L publication Critical patent/IE45352L/en
Publication of IE45352B1 publication Critical patent/IE45352B1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/001Enzyme electrodes
    • C12Q1/005Enzyme electrodes involving specific analytes or enzymes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

1523270 Determination of polyunsaturated fatty acids CHEMBRO HOLDINGS (PTY) Ltd 27 June 1977 [1 July 1976] 26785/77 Heading G1B Polyunsaturated fatty acid levels in a body fluid are determined using a reagent comprising a 0À1 to 2 molar borate buffer pH 7 to 10 which contains an oxygenese enzyme which is specific for polyunsaturated fatty acids containing a cis, cis - 1, 4-pentadiene system, for example lipo-oxygenase, the free acids or their salts being oxidized with molecular oxygen in the presence of the reagent and the amount of oxygen consumed being measured using an oxygen electrode. Linoleic acid in absolute alcohol solution may be used as-a standard.

Description

THIS invention relates to a novel method for the measurement of polyunsaturated fat, i.e. fatty acid, levels in body fluids such as serum or plasma and to a reagent for use in this method.
The measurement of polyunsaturated fatty acid levels in body fluids, particularly serum and plasma, is a useful procedure in the clinical pathology laboratory or physician's rooms for monitoring the effects of diet and treatments On body fluid polyunsaturated fatty acid levels particularly in conditions associated with atherosclerosis and hypercholesterolaemia. The lengthy assay time of present established procedures for determining polyunsaturated fatty acid levels and the specialized equipment required prevents routine analysis on a wide scale at ths present time.
Linoleic (?, 12-octadecadienoic), linolenic (9, 12,-15octadecatrienoic) and arachidonic (5, 8, 11, 14-eicosatetraenoic) acids constitute the three main polyunsaturated fatty acids present in serum or plasma together with small amounts of pentaenoic and haxaenoic fatty acids. All of these acids contain the cis, cis-1,4pentadiene system.. Of-these acids, linoleic acid is present in the greatest concentrations up to 55%). Lir.ol&*e, l'nolenic and arachiconic acids are sometimes referred to as tne essential fatty acids, that is, those fatty acids that cannot te biosyntnesisec! or β are synthesised in inadequate amounts by animals that require these nutrients for growth, maintenance and proper functioning of many physical ?: r--esses. Fulyuns^turatod 'atty acids constitute normally between 25 and 40% (w/v) of the total fatty acid content and are ther-a10 fore present in normal subjects in the range 0.75 to 2,00 gy litre.
According to the invention, there is provided a method of determining the polyunsaturated fatty acid levels in a body fluid ir.clyc'oc the steps of converting the polyun15 saturated fatty -rid content of a sample of body fluid into free acid or salt form, taking a predetermined volume of this body fluid, oxidising the polyunsaturated fatty acids or salts in the volume of body fluid with molecular oxygen in the presence o ' excess of ar. oxygenase enzyne which is specific for polyunsaturated fatty acids which contain a cis,ci3-'!34-r-;r-t3£liene system in a suitable buffer, and maasuring ihe amount of oxygon consulted by the voliwis of oody fluid by ::-.-0 or; oxygon alec .rode. - 3 An Oxygen electrode is relatively inexpensive and enables the amount of oxygen consumed to be determined rapidly and in highly turbid or coloured solutions. The oxygen electrode is a polargraphic device for measuring the con5 centration of oxygen dissolved in a given medium and depends on the electrolysis of dissolved oxygen at a weakly negative electrode.' The oxygen electrode has been known since the early part of this century. In 1956, Clark improved the electrode considerably by using an oxygen permeable, non10 conducting membrane to isolate the electrolytic cell from the sample under measurement - Clark» L.C.» Trans. Am. Soc. Art. Int. Org. 2, 41, 1956. Oxygen electrodes are commercially available. The oxygen electrode can be coupled in known manner to a standard recorder such as a Cimatic Cimapot T5 Recorder for following and recording the rate and amount of oxygen consumption.
The amount of oxygen consumed by the body fluid is directly proportional to the amount of polyunsaturated fatty acids in the body fluid. - Since a sample of body fluid of pre20 determined volume is used the concentration of polyunsaturated fatty acids in'the body fluid can be readily calculated. The oxygen electrode measures the amount of oxygen consumed and the amount of oxygen consumed is 53 5 3 deternrined when equilibrium conditions arc reached.
Sufficient molecular oxygen must, or course, be present to ensure that the content of polyunsatur·?:ed fatty acids or salts in the predetermined volume is oxidised. It is a simple matter to ensure that sufficient molecular oxygen is present because the likely concentrations of polyunsaturated fatty acids presen., in body fluids is known. The source of molecular oxygen is usually air saturated solutions.
Tha time it takes for equilibrium conditions to be reached is a function of the activity of the enzyme present. The greater the activity the quicker will the equilibrium conditions be reached. In ail cases, however, there must be an excess of enzyme, i.e. sufficient enzyme activity present to catalyse the reaction and overcome any inhibiting effect of monounsaturated and saturated fatty acids present m body fluids. The amount of enzyme necessary is determinable Without difficulty because the likely concentrations fatty acids in body fluids are known.
Polyunsaturated fatty acids are present in body fluids in the form of esters. Ic is necessary to convert the esters into the free acid or salt form, prior to oxidation, It is preferred that the esters be converted into the salt form and this can conveniently be achieved by means of saponification.
Saponification, as is Known in the art, involves reacting an ester, usually with heat, with aqueous alkali, e.g. sodium or potassium hydroxide, to form an alcohol and the salt of the acid corresponding to the ester. Saponification is preferably achieved by means of a methanolic potassium hydroxide solution. li is a surprising aspect and an advantage of the invention that - 5 43352 the oxidation can be performed on the salts of the acids.
If desired, the esters can be converted into free acid form.
This is conveniently achieved by means of saponification followed by acidification, e.g. with a mineral acid such as hydrochloric acid, or by enzymic hydrolysis using for example lipases, cholesterol esterases or phospholipases. By using selected enzymes it is possible to determine the levels of polyunsaturated fatty acids esterified wiiftchol esterol, glycerol or phospholipids. The oxygenase enzyme is preferably lipoxygenase (Linoleate: oxygen oxidoreductase E.C. No. 1.13.11.12).
The preferred buffer is one having a pH of 7 to 10. A particularly suitable buffer is a borate buffer of molarity 0.1 to 2.0 preferably 1.0, and a pH in the above range, a reagent comprising preferably 9. The invention includes within its scope/an 15 oxygenase enzyme specific for polyunsaturated fatty acids which contain a cis,cis-l,4-pentadiene system in a preferred buffer as defined above.
The oxidation will generally take place at a temperature of 15 to 40°C. The method of the invention has a number of advantages over known methods of determining polyunsaturated fatty acid levels in body fluids such as the gas chromatographic - 6 method. The method of the invention is very rapid and utilises vary small quantities of body fluids. Furthermore, as is mentioned above, it is not necessary to convert the esters of the body fluids into the free acids as the salts may bs used.
An example of the invention will now be described. The following reagents were used: Soya Bean Lipoxygenase: This was purchased from ililes10 Seravac, Cape Town, with an activity of 50 000 uriits/mg.
One unit is defines by the manufacturers as the amount of enzyme which causes an increase in absorbance at 234 nm, due to the oxidation of linoleic acid, of 0,00] per minute at 25°C. SO 000 .'-iles-Seravac units - 6 International IS Units at 2Sr'C. This value was in fast obtained cn assaying ths lipoxygenase in the oxygen electrode with linoleic acid as substrate. Enzyme solutions were prepared by dissolving approximately 50 mg lipoxygenase in 1.0 ml of 1,0 M potassium borate buffer, pH 9.0.
Linoleic acid solution: A standard solution was made by dissolving 80 pt (72 mg) linoleic acid in 10 ml absolute ethanol (25 - 6 mi cromol es /ml). - 7 453 5 2 Buffer System: 1,0 M potassium borate buffer, pH 9.0 was used as the buffer for all .experiments. This was prepared by dissolving 61,83 g crystalline boric acid in 500 ml distilled water and adding 20% (w/v) aqueous KOH to bring the pH to 9.0. The volune of this solution was then made to 1 litre by further addition of distilled water.
Methanolic-KOH: 14.3 g of potassium hydroxide were dissolved in 100 ml of methanol.
The oxygen consumption was measured using a commercially available oxygen electrode connected to a circulating water bath. The electrode was covered by an 0.0005 inch Teflon membrane, and the cell volume was maintained at 1.5 ml. The output signal was recorded by means of a cimatic Cimapot T5 recorder. The recorder was calibrated using air saturated water. The oxygen concentrations in air saturated solutions were calculated by the method of Glasstone (Glasstone S, Elements of Physical Chemistry, 1st Ed. pp 343-344, 1946, D. van Nostrand Co. Inc. New York).
In order to confirm that one molecule of oxygen is consumed - 8 45352 per molecule of polyunsaturated fatty acid, an experiment was carried out to record the oxygen consumption obtained on addition of varying amounts of linoieie acid to a solution containing lipoxygenase. Linoieie acid was chosen because it is the major constituent of polyunsaturated fatty acids in body fluids. 1.5 ml of ihe potassium borate buffer were added to the oxygen electrode cell together with varying volumes (1 to 6 pt) of the standard linoieie acid solution. After thermal equilibration of the mixture at 37°C, 100 p£ of lipoxygenase solution were added to start the reaction. Equilibrium conditions were reached after two or three minutes, and the amount of oxygen consumed after five minutes was plotted against the amount of linoieie acid {pmoles) added- The results are shown in the attached graph from i.hich it can be seen that the stoichiometry of the reaction is 1:1. In the graph the amount of linoieie acid added in pnrales is plotted along the abscissa and the total oxygen consulted in umoies is plotted along the ordinate.
The method of the invention was then carried out on serum and plasma. 50 of plasma or serum were pipetted into - 9 3352 a small test-tube, 0-12 ml of the methanolic-KOH solution added and the tube covered arid placed in a water-bath at 60°C for 10 minutes. The contents of the tubes after cooling were made up to 0.25 ml with methanol. 25 μί. of the resulting solution were then added to 1.5 ml of the borate buffer in the reaction-chamber of the oxygen electrode. After temperature equilibration had been achieved at 37°C, the reaction was initiated by addition of 100 μ£ of the lipoxygenase solution (~5 mg).
Equilibrium conditions were attained within 5 minutes, and the total oxygen consumed after 5 minutes was calculated from the recorder reading. . Because of the direct relationship between the oxygen consumed and content of polyunsaturated fatty acids in the serum and plasma this reading gave the number of micromoles of polyunsaturated fatty acids present in the sample. Since the volume of the sample is known, the concentration of polyunsaturated fatty acids in the serum and plasma can be readily calculated.

Claims (13)

1. A method of determining the polyunsaturated fatty acid levels in a body fluid including the steps of converting the polyunsaturated fatty acid content of a sample of body fluid into free acid or salt form, taking a predetermined
2. A method according to claim 1 wherein the body fluid is serum or plasma.
3. A method according to claim 1 or claim 2 wherein the 15 oxygenase enzyme is lipoxygenase.
4. A method according to any one of the preceding claims wherein the buffer is one having a pH of 7 to 10.
5. The buffer is a borate buffer having a molarity of 1.0 and a pH of 9. 5 volune of this body fluid, oxidising the polyunsaturated fatty acids or salts in the volume of body fluid with molecular oxygen in the presence of excess of an oxygenase enzyme which is specific for polyunsaturated fatty acids which contain a Cis,cis-1,4 pentadiene system in a suitable buffer, and
6. A method according to any one of claims 1 io 3 wherein
7. A method according to any one of the preceding claims wherein the polyunsaturated fatty acid content of the body fluid is converted into salt form by saponification.
8.
9. A method according to claim 1 substantially as herein described.. 45353
10. A reagent for use in the method of any one of the preceding claims comprising a borate buffer of molarity 0.1 to 2 molar and pH 7 to 10 and containing an oxygenase enzyme which is specific for polyunsaturated fatty acids containing a cis,cis-l,4-pentadiene system. 10 A method according to claim 7 wherein the saponification is achieved by means of a methanolic potassium hydroxide solution. 10 measuring the’ amount of oxygen consumed by the volume, of body fluid by means of an oxygen electrode.
11. A reagent according to claim 10 having a molarity of 1,0 and a pH of 9, - 11 45352 ,5. A method according to any one of the preceding claims wherein the buffer is a borate buffer having a molarity of 0,1 to 2
12. A reagent according tc claim 10 or 11 wherein the oxygenase enzyme is lipoxygenase,
13. A reagent recording to claim 10 substantially as herein described.
IE1374/77A 1976-07-01 1977-07-01 Determation of polyunsaturated fat levels in body fluids IE45352B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ZA00763930A ZA763930B (en) 1976-07-01 1976-07-01 Determination of polyunsaturated fat levels in body fluids

Publications (2)

Publication Number Publication Date
IE45352L IE45352L (en) 1978-01-01
IE45352B1 true IE45352B1 (en) 1982-08-11

Family

ID=25570462

Family Applications (1)

Application Number Title Priority Date Filing Date
IE1374/77A IE45352B1 (en) 1976-07-01 1977-07-01 Determation of polyunsaturated fat levels in body fluids

Country Status (11)

Country Link
JP (1) JPS5310494A (en)
AU (1) AU506806B2 (en)
BE (1) BE856304A (en)
CA (1) CA1095388A (en)
DE (1) DE2728987A1 (en)
FR (1) FR2356940A1 (en)
GB (1) GB1523270A (en)
IE (1) IE45352B1 (en)
NL (1) NL7707292A (en)
SE (1) SE7707620L (en)
ZA (1) ZA763930B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58126798A (en) * 1982-01-21 1983-07-28 Toyo Jozo Co Ltd Novel method for determination of unsaturated fatty acid
EP1682671A1 (en) * 2003-10-29 2006-07-26 Novozymes A/S Screening for lipolytic enzyme or amidase activity

Also Published As

Publication number Publication date
FR2356940A1 (en) 1978-01-27
GB1523270A (en) 1978-08-31
SE7707620L (en) 1978-01-02
CA1095388A (en) 1981-02-10
JPS5310494A (en) 1978-01-30
BE856304A (en) 1977-12-30
DE2728987A1 (en) 1978-01-05
AU2631677A (en) 1979-01-04
AU506806B2 (en) 1980-01-24
IE45352L (en) 1978-01-01
ZA763930B (en) 1978-02-22
NL7707292A (en) 1978-01-03

Similar Documents

Publication Publication Date Title
US4245041A (en) Triglycerides assay and reagents therefor
US4242446A (en) Method for determining a substance in a biological fluid and reagent combination for use in the method
JPS5886083A (en) Stabilizing agent for glycerol-3-phosphoric acid oxidase
US4212938A (en) Reagent and method for the determination of cholesterol
US4399218A (en) Method and reagent for the determination of glycerin
Mizutani et al. Determination of glutamate pyruvate transaminase and pyruvate with an amperometric pyruvate oxidase sensor
US4394445A (en) Enzymatic glyceride hydrolysis
JP2837273B2 (en) Analytical method
Della Ciana et al. Highly sensitive amperometric measurement of alkaline phosphatase activity with glucose oxidase amplification
US4271265A (en) Method and reagent for the determination of glutamate-oxalacetate transaminase and glutamate-pyruvate transaminase
US5512429A (en) Assay for enzyme activity
CA1225950A (en) Nad(p)-independent glycerol dehydrogenase
US4006061A (en) Lactate dehydrogenase determination method
IE45352B1 (en) Determation of polyunsaturated fat levels in body fluids
US4042462A (en) Creatine phosphokinase determination method
EP0493426B1 (en) Assay for enzyme activity
US4347313A (en) Analytical determination of lipase
US4012287A (en) Method and reagent for the quantitative analysis of triglycerides
JPH0220239B2 (en)
Passingham et al. An ensymic method for the preparation of millimole quantities of d (−)-β-hydroxybutyrate
Brash et al. Lipoxygenase metabolism of endogenous and exogenous arachidonate in leukocytes: GC-MS analyses of incubations in H218O buffers
JPH0650299B2 (en) Salicylate detection method
US4059490A (en) Measurement of alkaline phosphatase levels in body fluids
Satoh [18] Biomedical applications of the enzyme thermistor in lipid determinations
Ngo et al. Amperometric determination of picomolar levels of flavin adenine dinucleotide by cyclic oxidation-reduction in apo-glucose oxidase system